{‘She possesses zero qualifications’: this US medical field girds for Høeg's role at the FDA.

While the US undertakes sweeping revisions to its immunization schedules, one figure has surfaced unexpectedly: Høeg, a US-based sports physician and epidemiologist who first made her name by questioning coronavirus vaccines in the pandemic and has concentrated on possible fatalities following COVID-19 immunization in her short position at the FDA.

Scheduled Shifts to Childhood Vaccine Program

Agency leaders were set to unveil major revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish vaccine program, sources say – a major change that would place the US at odds with much of the global community with insufficient data for improved outcomes. This reveal has been postponed until the coming year.

Rather than Vinay Prasad, Dr. Høeg is set to present at the gathering. She was recently named acting director of the FDA’s CDER, the fifth individual to lead the center this year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the drug and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon rolling back already-approved vaccines at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric immunization guidelines in the US to become more in line with Denmark, a country with universal health coverage and a number of inhabitants approximately the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccination policy – typically the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Expertise

Dr. Høeg has little discernible experience in pharmaceutical research, approval processes or leadership, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She appears not to have any of the qualifications” for running the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a major agency. She is not an expert in industry regulation.”

Previous heads of the center would “understand legal statutes and the science of medication creation”, commented a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that former directors who led CBER have had.”

CDER has an vast portfolio at the FDA, she stated.

“The public just pays attention on the innovative therapies, but the generic program approves thousands of generic drugs. There is also a biosimilars division, OTC medication office and other areas, and each of these need to be managed,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative aspect to the position, which manages over 5,000 employees. “It’s a enormous leadership role, if you execute it properly,” Woodcock said.

Response and Disputed Policies

When asked about inquiries about Dr. Høeg's fitness for the role and whether this assignment represents increased cooperation among FDA leaders on vaccines, a spokesperson said that the “concerns rely on incorrect premises”.

“Her experience aligns with the duties of her role,” the representative explained, pointing to the period Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the agency head's controversial fast-track approval initiative, a contentious expedited therapy clearance system that reportedly worried her preceding directors. “How are these medications being chosen for this voucher program? Who makes the choices?” Howard questioned. “There is a lot of confidentiality going on at the FDA right now.”

Overall, he said, “the agency appears to be shifting towards laxer regulations of pharmaceuticals, aside from shots.”

Documented Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if troubling, track record, some experts have noted. She released a study using unverified public submissions to assess the incidence of heart inflammation after COVID-19 vaccination. She advised the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the current government included revising regulations for novel immunizations and halting “non-essential” vaccines, she stated following the vote on a online show. At the agency, Dr. Høeg has reportedly suggested excluding adolescent males from receiving Covid vaccinations.

“She’s an all-around dogmatist who commences with her preconceived notions and reverse-engineers to retrofit the data in a highly deceptive, fraudulent fashion,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of other skeptics, {like|